

28 July 2016

**QUARTERLY REPORT (ASX : BD1)
FOR THE PERIOD ENDING 30 JUNE 2016**

EARLY DETECTION OF LUNG CANCER

BARD1 Life Sciences Limited (**BARD1** or **Company**) listed on the ASX on 20 June, 2016 by way of a Prospectus which raised \$3m at 2c per share following the acquisition of the Geneva based Company BARD1AG SA.

As a consequence, Dr Irmgard Irminger and Professor Geoff Laurent joined the Board.

Dr Irmgard Irminger-Finger, PD, PhD

Irmgard is the head of the Molecular Gynecology and Obstetrics Laboratory at the University of Geneva and the founder of BARD1AG. Irmgard is responsible for more than 40 publications on BARD1 and cancer.

Professor Geoffrey Laurent, PhD, FRCP(Hon), FRCPath

Professor Laurent is the Director of the Institute for Respiratory Health and Director of the Centre for Cell Therapy and Regenerative Medicine at UWA. Prior to these appointments he was Head of Department of Internal Medicine and Director of the Centre for Respiratory Research at University College London. He was awarded the European Respiratory Societies Presidential Award for his contribution to lung science. He is Editor-in-Chief of the International Journal of Biochemistry and Cell Biology and has published over 250 peer reviewed articles in international journals of biomedical research.


As a result of the takeover Dr Irminger becomes the largest Shareholder in BARD1 and the University of Geneva becomes the fifth largest.

EXCEPTIONAL PRELIMINARY RESULTS

BARD1AG had been developing a biomarker for the early detection of lung Cancer by way of a standard blood test.

The results from the first blood samples are promising and are best illustrated by comparing them to the current industry standard achieved with CT Scans.

BARD1 Lung Cancer (BD1) Performance



This preliminary data suggests that the BD1 lung cancer test is superior to other current methods for lung cancer detection

The ROC Curve measures the true positive sensitivity and the false positive sensitivity of the test. The closer to the diagonal the LESS accurate is the test. A paper describing these results in detail is currently being prepared for publication.

The next phase for BARD1 is to take its lung cancer test beyond the “proof of concept” stage by both increasing the sample size from the initial 200 (of which approximately half were controls, that is people with no history of lung cancer) and by improving the technical aspects of the test. To that end BARD1 has contracted with Meso Scale Diagnostics, LLC. (**Meso Scale**) in Maryland USA.

Meso Scale is a global leader in the development, manufacture and commercialisation of innovative assays and instruments for the measurement of molecules in biological samples.

BARD1 is collecting additional blood samples from centres in Europe and will have approximately 450 samples ready to be analysed using the Meso Scale test this calendar year.

INTELLECTUAL PROPERTY

During the quarter BARD1 has spent considerable effort enhancing the scope and integrity of its Intellectual Property surrounding the BARD1 protein.

Based on some very preliminary data and IP owned by BARD1, the Company believes that there is potential for BARD1 to act as an accurate Biomarker for other cancers including breast, ovarian and colon.

Furthermore, the company has done some preclinical tests indicating that BARD1 is immunogenic and capable of slowing ovarian tumour growth, raising the potential for the development of a vaccine at some point in the future.

NEXT PHASE

The listing of BARD1 on the ASX represents the start of the next stage in the development of the science surrounding the BARD1 protein since Dr Irminger first demonstrated its function and potential in 1998.

Further results over the next 18 months will determine how big an impact BARD1 may have in the fight against lung cancer and the potential of BARD1 screening as a test for other cancers.

For and on behalf of the Board of Directors.

PETER GUNZBURG

Executive Chairman

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

BARD1 LIFE SCIENCES LIMITED (formerly Eurogold Limited)

ABN

58 009 070 384

Quarter ended ("current quarter")

30 June 2016

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (12 months) \$A'000 |
|---|------------------------------------|---|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | 0 | 0 |
| 1.2 Payments for | | |
| (a) Research, development, Patents | (76) | (76) |
| (b) product manufacturing and operating costs | 0 | 0 |
| (c) advertising and marketing | 0 | 0 |
| (d) leased assets | 0 | 0 |
| (e) staff costs | (55) | (55) |
| (f) administration and corporate costs | (86) | (375) |
| 1.3 Dividends received (see note 3) | 0 | 0 |
| 1.4 Interest received | 1 | 7 |
| 1.5 Interest and other costs of finance paid | 0 | 0 |
| 1.6 Income taxes paid | 0 | 0 |
| 1.7 Government grants and tax incentives | 0 | 0 |
| 1.8 Other (provide details if material) | 0 | 0 |
| 1.9 Net cash from / (used in) operating activities | (216) | (499) |

| | | |
|--|-------|-------|
| 2. Cash flows from investing activities | | |
| 2.1 Payments to acquire: | | |
| (a) property, plant and equipment | 0 | |
| (b) businesses (see item 10) | (310) | (595) |
| (c) investments | (25) | (25) |

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (12 months) \$A'000 |
|---|------------------------------------|---|
| (d) intellectual property | 0 | 0 |
| (e) other non-current assets | 0 | 0 |
| 2.2 Proceeds from disposal of: | | |
| (a) property, plant and equipment | 0 | |
| (b) businesses (see item 10) | 0 | 0 |
| (c) investments | 0 | 0 |
| (d) intellectual property | 0 | 0 |
| (e) other non-current assets | 0 | 0 |
| 2.3 Cash flows from loans to other entities | 0 | 0 |
| 2.4 Dividends received (see note 3) | 0 | 0 |
| 2.5 Other (provide details if material) | | 0 |
| 2.6 Net cash from / (used in) investing activities | (335) | (620) |

| | | |
|---|--------------|--------------|
| 3. Cash flows from financing activities | | |
| 3.1 Proceeds from issues of shares | 2,669 | 2,519 |
| 3.2 Proceeds from issue of convertible notes | 0 | 0 |
| 3.3 Proceeds from exercise of share options | 0 | 0 |
| 3.4 Transaction costs related to issues of shares, convertible notes or options | 0 | 0 |
| 3.5 Proceeds from borrowings | 0 | 0 |
| 3.6 Repayment of borrowings | 0 | 0 |
| 3.7 Transaction costs related to loans and borrowings | 0 | 0 |
| 3.8 Dividends paid | 0 | 0 |
| 3.9 Other (provide details if material) | 0 | 0 |
| 3.10 Net cash from / (used in) financing activities | 2,669 | 2,519 |

| | | |
|---|-------|-------|
| 4. Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 Cash and cash equivalents at beginning of quarter/year to date | 963 | 1,730 |
| 4.2 Net cash from / (used in) operating activities (item 1.9 above) | (216) | (499) |

| Consolidated statement of cash flows | | Current quarter \$A'000 | Year to date (12 months) \$A'000 |
|---|--|------------------------------------|---|
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (335) | (620) |
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 2,669 | 2,519 |
| 4.5 | Effect of movement in exchange rates on cash held | 11 | (38) |
| 4.6 | Cash and cash equivalents at end of quarter | 3,092 | 3,092 |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter \$A'000 | Previous quarter \$A'000 |
|------------|---|------------------------------------|-------------------------------------|
| 5.1 | Bank balances | 3,092 | 963 |
| 5.2 | Call deposits | 0 | 0 |
| 5.3 | Bank overdrafts | 0 | 0 |
| 5.4 | Other (provide details) | 0 | 0 |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 3,092 | 963 |

6. Payments to directors of the entity and their associates

6.1 Aggregate amount of payments to these parties included in item 1.2

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

| Current quarter \$A'000 |
|------------------------------------|
| 31 |
| 0 |

| |
|--|
| |
|--|

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

| 7. Payments to related entities of the entity and their associates | Current quarter \$A'000 |
|--|------------------------------------|
| 7.1 Aggregate amount of payments to these parties included in item 1.2 | 0 |
| 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 | 0 |
| 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2 | |

| 8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i> | Total facility amount at quarter end \$A'000 | Amount drawn at quarter end \$A'000 |
|--|---|--|
| 8.1 Loan facilities | 0 | 0 |
| 8.2 Credit standby arrangements | 0 | 0 |
| 8.3 Other (please specify) | 0 | 0 |
| 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well. | | |

| 9. Estimated cash outflows for next quarter | \$A'000 |
|--|----------------|
| 9.1 Research and development | 400,000 |
| 9.2 Product manufacturing and operating costs | |
| 9.3 Advertising and marketing | 20 |
| 9.4 Leased assets | 0 |
| 9.5 Staff costs | 80 |
| 9.6 Administration and corporate costs | 100 |
| 9.7 Other (provide details if material) | |
| 9.8 Total estimated cash outflows | 500,000 |

| 10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above) | Acquisitions | Disposals |
|---|---|-----------|
| 10.1 Name of entity | BARD1AG S.A | |
| 10.2 Place of incorporation or registration | Switzerland | |
| 10.3 Consideration for acquisition or disposal | Issue of 217,003,236 Ordinary Shares and 217,003,236 Performance Shares to the BARD1AG SWAP Vendors. Cash consideration of CH221,679.92 (A\$309,421) to the BARD1AG Cash Vendors. Issue of 12,500,000 to Universite of Geneve (UNIGE) in relation to the UNIGE Licence Agreement (Confirmatory Deed). | |
| 10.4 Total net assets | (309,614) | |
| 10.5 Nature of business | Cancer Research | |

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Company Secretary

Date: 28 July 2016

Print name: P Collinson

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.